Given the encouraging in vivo results in normal mice, we investigated the 134Ce radiochemistry of cancer-targeting radiopharmaceuticals, including the small-molecule prostate-specific membrane antigen (PSMA)–targeting agent PSMA-617 (23) and the CD46-targeting antibody derivative MACROPA-PEG4-YS5. The gene discussed is FOLH1; the disease is cancer.